+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Southern Blotting - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027-2032)

  • PDF Icon

    Report

  • 118 Pages
  • November 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6294763
The southern blotting market size is projected to expand from USD 2.43 billion in 2026 and USD 2.56 billion in 2027 to USD 3.30 billion by 2032, registering a CAGR of 5.21% between 2027 and 2032. This report is Segmented by Product Type (Instruments, Kits and Reagents, and Consumables), Application (Medical Diagnosis, and More), End User (Academic and Research Institutes, Pharma and Biotech Companies, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Southern Blotting Market Trends and Insights

Growth in Genomic Research and Precision Medicine

Precision medicine programs are increasing the number and variety of samples that need DNA-level characterization. Southern blotting remains useful where laboratories need both repeat size and methylation information from genomic DNA. A 2025 Human Genomics study found that germline variant diagnosis can remain incomplete when precision medicine programs rely on a single testing method. This supports a multi-method diagnostic role for the southern blotting market. Growth in research programs also increases demand for high-quality membranes, labeled probes, and reproducible detection systems.

Confirmatory Testing for Repeat Expansions and Structural Variants

Repeat expansion disorders continue to support demand in medical genetics laboratories. These disorders include fragile X syndrome, facioscapulohumeral muscular dystrophy, Huntington’s disease, and Friedreich’s ataxia. ACMG states that large repeat expansions detected by short-read NGS should ideally be confirmed with other methods, including southern blotting. An integrated 2026 FSHD workflow used single-molecule optical mapping as a first-line method and retained southern blot analysis for confirmation of contracted 4qA alleles. The South West Genomic Medicine Service paused routine FSHD1 southern blot testing during 2026 because of a supplier constraint, not because the test had become clinically unnecessary. The southern blotting market thus remains exposed to reagent availability, while its clinical role stays embedded in complex repeat expansion pathways.

Labor-Intensive and Low-Throughput Workflow

Southern blotting requires DNA extraction, restriction digestion, electrophoresis, transfer, hybridization, and detection. These steps can require 48 to 72 hours and include substantial hands-on work. High-volume laboratories can face capacity limits when the test is part of a broad diagnostic menu. A 2025 study of TCF4 repeat expansion testing characterized southern blotting as labor-intensive, low throughput, and dependent on microgram quantities of genomic DNA. Automation can reduce some handling, but it does not remove the core biochemical steps. This constraint limits broader adoption across the southern blotting market.

Other drivers and restraints analyzed in the detailed report include:

  1. Molecular Diagnostics and Genetic Testing Expansion
  2. Automation and Digital Detection Adoption
  3. Displacement by PCR, Digital PCR, Microarrays, and Sequencing

Segment Analysis

Instruments held 37.65% of the southern blotting market share in 2026. This position reflects the capital requirements for electrophoresis systems, transfer equipment, hybridization ovens, and digital imaging platforms. Manual and semi-automated systems remain relevant in academic laboratories and cost-sensitive clinical settings, while automated systems command higher revenue per unit and contribute to replacement-cycle spending. Consumables form the next major product group because nylon membranes, nitrocellulose membranes, gels, blotting papers, probes, and buffers are used repeatedly. Nylon membranes are favored for high-molecular-weight DNA because they can withstand multiple hybridization cycles.

Kits and reagents are forecast to grow at a 7.54% CAGR through 2032, the highest rate within product type. Laboratories are moving from radioactive labeling toward digoxigenin probes and chemiluminescent detection substrates that fit the installed base of CCD and near-infrared imaging platforms. Thermo Fisher Scientific’s Sequential Protein/DNA/RNA Extraction Kit, launched in February 2026, supports workflows that need high-quality DNA for NGS and downstream blotting. EU In Vitro Diagnostic Regulation requirements favor suppliers that provide validated quality documentation. The southern blotting industry can derive recurring revenue in the southern blotting market even where instrument purchases are less frequent.

Complete Report Scope:

  • By Product Type
    • Instruments
      • Manual Instruments
      • Automated Instruments
      • Semi-Automated Instruments
    • Kits and Reagents
      • Probe Labeling Reagents
      • Hybridization Buffers
      • Detection Substrates
    • Consumables
      • Nylon Membranes
      • Nitrocellulose Membranes
      • Filters and Blotting Papers
      • Gels and Transfer Accessories
  • By Application
    • Medical Diagnosis
    • Genetic Fingerprinting and Forensic Testing
    • Scientific Research
  • By End User
    • Academic and Research Institutes
    • Pharmaceutical and Biotechnology Companies
    • Clinical Laboratories
    • Other End User
  • Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America accounted for 42.76% of regional spending in 2026. Large reference laboratories, biopharma research campuses, and NIH-funded genomics facilities support the region’s broad use of validated genomic methods. U.S. laboratories use southern blotting in fragile X and FSHD pathways that require careful repeat expansion confirmation. College of American Pathologists accreditation expectations also support multi-method validation in molecular diagnostics. The NIH funded the 2025 NBSxWGS BEACONS initiative with up to USD 14.4 million for newborn screening through whole-genome sequencing. This investment expands genomic testing infrastructure and can raise demand for downstream confirmation methods. Canada is incorporating more genetic testing for neuromuscular and neurodegenerative conditions through provincial health programs. Mexico’s urban private diagnostics networks are also adding molecular biology capability. Automation is becoming more important in North American research settings because laboratories need higher reproducibility and better digital documentation. The southern blotting market in the region benefits from protocol continuity, quality requirements, and investment in advanced diagnostics.

Asia-Pacific is forecast to grow at a 6.43% CAGR through 2032. The region is moving from isolated genomic testing projects toward larger institutional and national genomics programs. India, China, Japan, South Korea, and Southeast Asian countries each contribute different sources of laboratory demand. QIAGEN opened a Melbourne bioinformatics data center in February 2025 to provide in-country data hosting for genomic testing laboratories in Australia. In China, Topgen Biomedical Technology operates a clinical network that spans more than 1,300 hospitals with CAP-accredited NGS capability. This scale can generate repeat expansion and structural variant findings that require confirmation in equipped laboratories. Japan and South Korea have mature genomic medicine programs and reimbursement systems that support multi-modal diagnostic pathways. Regional compliance factors include local diagnostic regulations, CAP accreditation, and health-data requirements. The southern blotting market size in Asia-Pacific is supported by growing laboratory capacity, even as newer long-read methods expand. Vendors that offer application support and reliable reagent distribution have a stronger opportunity across diverse laboratory settings.

Europe is shaped by IVDR implementation, which extends conformity assessment timelines for some probe-based diagnostic kits. German and French laboratories are responding by emphasizing validated suppliers with documented quality systems. The United Kingdom’s NHS genomic network continues to use southern blotting for FSHD despite isolated reagent supply constraints. Germany’s university hospitals and research institutes also sustain demand for instruments and consumables. Middle East and Africa remain earlier-stage opportunities, with Saudi Arabia’s healthcare investment and South Africa’s academic medical centers supporting molecular diagnostics expansion. Brazil drives much of South American demand through rare disease diagnostics programs and academic molecular biology research. Argentina and other countries follow laboratory procurement cycles that depend on health ministry budgets. Reagent supply reliability and specialized operator availability remain common constraints across these areas. ISO 13485 and ISO 15189 documentation has growing regulatory influence in procurement decisions. Use outside North America and Asia-Pacific depends on distributors that can combine product availability with technical support.



List of Companies Covered in this Report:

  1. Thermo Fisher Scientific
  2. Bio-Rad Laboratories
  3. Agilent Technologies
  4. Merck
  5. PerkinElmer
  6. QIAGEN
  7. Cleaver Scientific Ltd.
  8. Pall
  9. Promega
  10. Takara Bio
  11. Advansta
  12. Azure Biosystems
  13. LI-COR Biosciences
  14. Abcam
  15. Sartorius
  16. Analytik Jena GmbH
  17. Geno Technology, Inc.
  18. Enzo Biochem
  19. Rockland Immunochemicals

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope Of The Study
2 Research Methodology3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growth in Genomic Research and Precision Medicine
4.2.2 Demand for Confirmatory Analysis of Repeat Expansions and Structural Variants
4.2.3 Expansion of Molecular Diagnostics and Genetic Testing Infrastructure
4.2.4 Rising Use in Transgene, Gene-Structure, and Cell-Line Characterization
4.2.5 Adoption of Automated Transfer, Imaging, and Chemiluminescent Detection
4.2.6 Continued Need for High-Molecular-Weight DNA Confirmation
4.3 Market Restraints
4.3.1 Labor-Intensive and Low-Throughput Workflow
4.3.2 Displacement by PCR, Digital PCR, Microarrays, and Sequencing
4.3.3 Large DNA Input Requirement and Sample-Quality Sensitivity
4.3.4 Specialized Skills, Validation Burden, and Variable Reagent Availability
4.4 Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat Of New Entrants
4.7.2 Bargaining Power Of Buyers
4.7.3 Bargaining Power Of Suppliers
4.7.4 Threat Of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Product Type
5.1.1 Instruments
5.1.1.1 Manual Instruments
5.1.1.2 Automated Instruments
5.1.1.3 Semi-Automated Instruments
5.1.2 Kits and Reagents
5.1.2.1 Probe Labeling Reagents
5.1.2.2 Hybridization Buffers
5.1.2.3 Detection Substrates
5.1.3 Consumables
5.1.3.1 Nylon Membranes
5.1.3.2 Nitrocellulose Membranes
5.1.3.3 Filters and Blotting Papers
5.1.3.4 Gels and Transfer Accessories
5.2 By Application
5.2.1 Medical Diagnosis
5.2.2 Genetic Fingerprinting and Forensic Testing
5.2.3 Scientific Research
5.3 By End User
5.3.1 Academic and Research Institutes
5.3.2 Pharmaceutical and Biotechnology Companies
5.3.3 Clinical Laboratories
5.3.4 Other End User
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles {(Includes Global Level Overview, Market Level Overview, Core Segments, Financials As Available, Strategic Information, Market Rank/Share For Key Companies, Products & Services, And Recent Developments)}
6.3.1 Thermo Fisher Scientific Inc.
6.3.2 Bio-Rad Laboratories, Inc.
6.3.3 Agilent Technologies, Inc.
6.3.4 Merck KGaA
6.3.5 PerkinElmer, Inc.
6.3.6 QIAGEN N.V.
6.3.7 Cleaver Scientific Ltd.
6.3.8 Pall Corporation
6.3.9 Promega Corporation
6.3.10 Takara Bio Inc.
6.3.11 Advansta, Inc.
6.3.12 Azure Biosystems, Inc.
6.3.13 LI-COR Biosciences
6.3.14 Abcam plc
6.3.15 Sartorius AG
6.3.16 Analytik Jena GmbH
6.3.17 Geno Technology, Inc.
6.3.18 Enzo Life Sciences, Inc.
6.3.19 Rockland Immunochemicals, Inc.
7 Market Opportunities & Future Outlook
7.1 White-Space & Unmet-Need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Merck KGaA
  • PerkinElmer, Inc.
  • QIAGEN N.V.
  • Cleaver Scientific Ltd.
  • Pall Corporation
  • Promega Corporation
  • Takara Bio Inc.
  • Advansta, Inc.
  • Azure Biosystems, Inc.
  • LI-COR Biosciences
  • Abcam plc
  • Sartorius AG
  • Analytik Jena GmbH
  • Geno Technology, Inc.
  • Enzo Life Sciences, Inc.
  • Rockland Immunochemicals, Inc.